Navigation Links
YM sees nimotuzumab license unaffected by civil claim against licensor
Date:3/2/2010

nts involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that JAK 1/2 and the VDA molecule will generate positive efficacy and safety data in future clinical trials; AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; that and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE YM BioSciences Inc.

Back to top
'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
2. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
3. YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009
4. YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG
5. YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO
6. YM BIOSCIENCES USA RECEIVES CLEARANCE FROM US TREASURY DEPARTMENT TO EXTEND CLINICAL PROGRAM FOR NIMOTUZUMAB
7. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
8. NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
9. YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
10. YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
11. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 02, 2015 Research ... of Jain PharmaBiotech,s new report "Biomarkers - ... This report follows the broad definition ... be objectively measured and evaluated as an indicator ... as pharmacological responses to a therapeutic intervention. Tests ...
(Date:6/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/l5jcdk/genotyping_market ) has announced ... Application & by Products - Global Forecast to 2020" ... genotyping market is expected to reach $17.0 Billion in ... of 22.3% during the forecast period of 2015 to ... the availability of a range of products for wide ...
(Date:6/2/2015)... --  Hospira, Inc. (NYSE: HSP ), a ... – a global biopharmaceutical company – has received approval ... Brazil – for Remsima (infliximab), ... Brazil . The medication will be ... infliximab in 26 European countries and in ...
(Date:6/2/2015)... “Stem Cell Therapy to help dogs suffering from ... used often as an adjunct to surgery in large specialty ... aware or comfortable enough with the techniques to offer it ... for the last resort cases - when nothing else works ... paw to get around. It is an easy procedure, and ...
Breaking Biology Technology:Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 2Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 3Genotyping Market Report 2015 by Technology, Application & by Products - Global Forecast to 2020 for the $17 Billion Market 2ANVISA Approves First Infliximab Biosimilar in Brazil 2ANVISA Approves First Infliximab Biosimilar in Brazil 3ANVISA Approves First Infliximab Biosimilar in Brazil 4ANVISA Approves First Infliximab Biosimilar in Brazil 5VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 2VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 3
... ChemoCentryx, Inc. today announced positive preclinical results for its ... the American Society of Nephrology. CCR2 inhibition in diabetic ... serum markers of renal function, and hyperglycemia.  These data ... Inhibition in Diabetic Mice Results in a Rapid and ...
... Nov. 10, 2011 Sequenom, Inc. (NASDAQ: SQNM ... today announced the Company,s participation at the Lazard Capital Markets ... York City November 15-16, 2011. Harry F. Hixson, ... Director and EVP of Research and Development, will present on ...
... The report " Lung Cancer Drugs ... http://www.marketsandmarkets.com/Market-Reports/lung-cancer-drugs-market-508.html ] " analyzes and studies the major ... Browse in-depth TOC on   ... 2020). Get Free 10% ...
Cached Biology Technology:ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology 2ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology 3Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference 2MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020 2MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020 3MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020 4
(Date:5/27/2015)... 27, 2015   Codonics (codonics.com), ... and image documentation solutions and Omnicell ... automation solutions, is pleased to announce their ... Safe Label System® (SLS), an award-winning FDA ... the Omnicell Anesthesia Workstation, helps prevent medication ...
(Date:5/22/2015)... -- According to a new market research ... Emotion, Forensic), by Software (Middleware, Databases), by Hardware (Cameras, Integrated ... Home) - Global Forecast to 2020", published by MarketsandMarkets, ... 2015 to $6.19 Billion by 2020, at a CAGR ... Tables and   43 Figures spread through 140 Pages ...
(Date:5/20/2015)... , May 20, 2015 NXT-ID, Inc. ... that its wholly owned subsidiary, 3D-ID LLC, a company ... Team Battelle for the biometrics technology portion of the ... Contract from the Department of the Army. ... products developed for government, law enforcement and security agencies. ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... 2009 - Collaboration in prostate cancer translational research in ... achieved in recent years but also to streamline current ... overlaps. This was amongst the goals of the two-day ... opened today in Amsterdam, The Netherlands. "It ...
... Outstanding International Horticulturist Award from the American Society for ... recognition of her longstanding and valuable contribution to international ... award on 25 July 2009 at the annual ASHS ... co-editor of the books Genetics and Genomics of Rosaceae ...
... -- Predation is one of the most fundamental and fascinating ... predators on Earth. However, their hunting pattern is difficult to ... a result, shark predatory behavior has remained much of a ... using geographic profiling -- a criminal investigation tool used to ...
Cached Biology News:Prostate Cancer Translational Research in Europe meeting: Search for biomarkers continues 2Prostate Cancer Translational Research in Europe meeting: Search for biomarkers continues 3Geographic profiling applied to track hunting patterns of white sharks in South Africa 2
Mouse monoclonal antibody to ST8SIA2 - ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2...
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse monoclonal antibody raised against a partial recombinant RAB11B. NCBI Entrez Gene ID = RAB11B...
...
Biology Products: